Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner Chilcott Femtrace Launch Expected In First Quarter 2005

Executive Summary

Warner Chilcott is planning an early 2005 launch for Femtrace following FDA approval of the hormone replacement therapy Aug. 20

You may also be interested in...



Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy

Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA

Hormone Therapy Dementia “Black Box” Warning Sought By FDA

FDA is recommending a hormone replacement therapy class "black box" warning on an increased risk of dementia with use of estrogen and combination estrogen/progestin products

Galen Femring Includes HRT Class Labeling; Launch In June

Labeling for Galen's vaginal hormone therapy Femring follows the template established for Wyeth's Premarin family to incorporate the findings from NIH's Women's Health Initiative study

Related Content

Topics

UsernamePublicRestriction

Register

PS044592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel